Safety: related to the use of inhalational high molecular weight heparin in patients with SARS-COV-2 through the assessment of hemorrhagic events of any nature; alteration of the coagulogram that indicates an increase in Activated Partial Thromboplastin Time (APTT)> 1; 5 and heparin-induced thrombocytopenia.;Efficacy: relative to the proposed treatment; through the analysis of the viral load of the SARS-COV-2 virus in the participants treated by the sequential evaluation of the viral load in RT-PCR of nasal Swab.

Safety: related to the use of inhalational high molecular weight heparin in patients with SARS-COV-2 through the assessment of hemorrhagic events of any nature; alteration of the coagulogram that indicates an increase in Activated Partial Thromboplastin Time (APTT)> 1; 5 and heparin-induced thrombocytopenia.;Efficacy: relative to the proposed treatment; through the analysis of the viral load of the SARS-COV-2 virus in the participants treated by the sequential evaluation of the viral load in RT-PCR of nasal Swab.